Das George-Huntington-Institut

IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner

The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the European Union to support the development of sensorbased technologies to assess the severity of global functional deficits of patients with different diseases including Huntington's disease in everyday settings. GHI is responsible to conduct the feasibility study in HD and to coordinate the validation study across several European HD centers.

Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021

Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...

Read More
PROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020

GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...

Read More
SHIELD-HD Study of Triplet Therapeutics started at GHI
September 24, 2020

nan

Read More
Erreichbarkeit während der Umzugsphase
June 22, 2020

Liebe Patienten, Angehörige und Interessenten,

 

aufgrund des Umzugs sind die...

Read More
IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019

The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...

Read More